Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsLTS:0L35 +1.26%57 Interest Coverage is 2.43 as of Jun. 2026, which is 80% below its 10-year median of 11.86. GuruFocus rates LTS:0L35 with a GF Score™ of 57/100 and a GF Value™ of $115.82 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 372 Biotechnology companies, Sarepta Therapeutics ranks worse than 268816.94% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Sarepta Therapeutics's
Operating Income
for the
three
months ended in Jun. 2026 was $52 Mil. Sarepta Therapeutics's Interest Expense for the
three
months ended in Jun. 2026 was $-22 Mil.
Sarepta Therapeutics's interest coverage for the quarter that ended in Jun. 2026 was 2.43.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Sarepta Therapeutics's Interest Coverage or its related term are showing as below:
LTS:0L35's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.135 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Sarepta Therapeutics Interest Coverage Related Terms
Sarepta Therapeutics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0L35 vs MPLT, ZYME, ABCL: Interest Coverage Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (LTS:0L35) has a Interest Coverage of 2.43 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sarepta Therapeutics and its competitors. This is 80% below median its historical median of 11.86. According to the industry distribution chart, Sarepta Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry.
Is Sarepta Therapeutics' Interest Coverage too high?
Sarepta Therapeutics' current Interest Coverage of 2.43 is 80% below median its 10-year median of 11.86. The Biotechnology industry median Interest Coverage is 106.14. Sarepta Therapeutics' value of 2.43 is 97.7% below this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Interest Coverage compare to MPLT and ZYME?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #999999 out of 372 companies for Interest Coverage. This places Sarepta Therapeutics in the lower half of its industry. The industry median Interest Coverage is 106.14. Sarepta Therapeutics' value of 2.43 is 97.7% below this benchmark. While the company's 10-year median is 11.86 vs. the industry median of 106.14, Sarepta Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Interest Coverage of 2.43 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Interest Coverage is 2.43, which is 80% below median its own 10-year median of 11.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $115.82, compared to a current price of $16.91 — trading 85.4% below its estimated fair value. The current Interest Coverage is 2.43, which is 80% below median its 10-year median of 11.86 and 97.7% below the Biotechnology industry median of 106.14. Sarepta Therapeutics' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Interest Coverage is 2.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $16.91 is trading 85.4% below its estimated GF Value™ of $115.82.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Interest Coverage: 2.43 (80% below median its 10-year median of 11.86)
GF Value™: $115.82 vs. price of $16.91 (85.4% below fair value)
Industry Position: 97.7% below the Biotechnology median (#999999 of 372)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
57GF Score
Get the complete analysis for LTS:0L35
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
